An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Conditions: Multiple Myeloma Interventions: Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection Sponsors: Changzhou No.2 People ' s Hospital Not yet recruiting

Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials